{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:45:58Z","timestamp":1778345158501,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cheminform"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Structure-based drug repositioning has emerged as a promising alternative to conventional drug development. Regardless of the many success stories reported over the past years and the novel breakthroughs on the AI-based system AlphaFold for structure prediction, the availability of structural data for protein\u2013drug complexes remains very limited. Whereas the chemical libraries contain millions of drug compounds, the vast majority of them do not have structures to crystallized targets,and it\u00a0is, therefore, impossible to characterize their binding to targets from a structural view. However, the concept of building blocks offers a novel perspective on the structural problem. A drug compound is considered a complex of small chemical blocks or fragments, which confer the relevant properties to the drug and have a high proportion of functional groups involved in protein binding. Based on this, we propose a novel approach to expand the scope of structure-based repositioning approaches by transferring the structural knowledge from a fragment to a compound level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We fragmented over 100,000 compounds in the Protein Data Bank (PDB) and characterized the structural binding mode of 153,000 fragments to their crystallized targets. Using the fragment\u2019s data, we were able to artificially reconstruct the binding mode of over 7,800 complexes between ChEMBL compounds and their known targets, for which no structural data is available. We proved that the conserved binding tendency of fragments, when binding to the same targets, highly influences the drug\u2019s binding specificity and carries the key information to reconstruct full drugs binding mode. Furthermore, our approach was able to reconstruct multiple compound-target pairs at optimal thresholds and high similarity to the actual binding mode.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Such reconstructions are of great value and benefit structure-based drug repositioning since they automatically enlarge the technique\u2019s scope and allow exploring the so far \u2018unexplored compounds\u2019 from a structural perspective. In general, the transfer of structural information is a promising technique that could be applied to any chemical library, to any compound that has no crystal structure available in PDB, and even to transfer any other feature that may be relevant for the drug discovery process and that due to data limitations is not yet fully available. In that sense, the results of this work document the full potential of structure-based screening even beyond PDB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13321-022-00592-w","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T12:03:55Z","timestamp":1647345835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening"],"prefix":"10.1186","volume":"14","author":[{"given":"Melissa F.","family":"Adasme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Naomi","family":"Bolz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Al-Fatlawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-6949","authenticated-orcid":false,"given":"Michael","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"issue":"1","key":"592_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C et al (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41\u201358","journal-title":"Nat Rev Drug Discov"},{"key":"592_CR2","doi-asserted-by":"crossref","unstructured":"Adasme MF, Parisi D, Sveshnikova A, Schroeder M (2020) Structure-based drug repositioning: Potential and limits. Semin Cancer Biol","DOI":"10.1016\/j.semcancer.2020.01.010"},{"issue":"1","key":"592_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1021\/jm049312t","volume":"48","author":"C Chuaqui","year":"2005","unstructured":"Chuaqui C, Deng Z, Singh J (2005) Interaction profiles of protein kinase\u2014inhibitor complexes and their application to virtual screening. J Med Chem 48(1):121\u2013133","journal-title":"J Med Chem"},{"issue":"4","key":"592_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1021\/ci300200r","volume":"53","author":"V Chupakhin","year":"2013","unstructured":"Chupakhin V, Marcou G, Baskin I, Varnek A, Rognan D (2013) Predicting ligand binding modes from neural networks trained on protein\u2013ligand interaction fingerprints. J Chem Inform Model 53(4):763\u2013772","journal-title":"J Chem Inform Model"},{"issue":"7","key":"592_CR5","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.bmcl.2005.12.071","volume":"16","author":"CS Li","year":"2006","unstructured":"Li CS, Deschenes D, Desmarais S, Falgueyret J-P, Gauthier JY, Kimmel DB, L\u00e9ger S, Mass\u00e9 F, McGrath ME, McKay DJ et al (2006) Identification of a potent and selective non-basic cathepsin k inhibitor. Bioorg Med Chem Lett 16(7):1985\u20131989","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"592_CR6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1021\/ci900043r","volume":"49","author":"VI P\u00e9rez-Nueno","year":"2009","unstructured":"P\u00e9rez-Nueno VI, Rabal O, Borrell JI, Teixid\u00f3 J (2009) Apif: a new interaction fingerprint based on atom pairs and its application to virtual screening. J Chem Inform Model 49(5):1245\u20131260","journal-title":"J Chem Inform Model"},{"issue":"11","key":"592_CR7","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1021\/jm8001058","volume":"51","author":"J Venhorst","year":"2008","unstructured":"Venhorst J, N\u00fanez S, Terpstra JW, Kruse CG (2008) Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. J Med Chem 51(11):3222\u20133229","journal-title":"J Med Chem"},{"issue":"W1","key":"592_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/nar\/gkv315","volume":"43","author":"S Salentin","year":"2015","unstructured":"Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M (2015) PLIP: fully automated protein\u2013ligand interaction profiler. Nucleic Acids Res 43(W1):443\u2013447","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"592_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-11924-4","volume":"7","author":"S Salentin","year":"2017","unstructured":"Salentin S, Adasme MF, Heinrich JC, Haupt VJ, Daminelli S, Zhang Y, Schroeder M (2017) From malaria to cancer: computational drug repositioning of amodiaquine using PLIP interaction patterns. Sci Rep 7(1):1\u201313","journal-title":"Sci Rep"},{"issue":"5","key":"592_CR10","doi-asserted-by":"publisher","first-page":"0233089","DOI":"10.1371\/journal.pone.0233089","volume":"15","author":"MF Adasme","year":"2020","unstructured":"Adasme MF, Parisi D, Van Belle K, Salentin S, Haupt VJ, Jennings GS, Heinrich J-C, Herman J, Sprangers B, Louat T et al (2020) Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor. PloS One 15(5):0233089","journal-title":"PloS One"},{"issue":"22","key":"592_CR11","doi-asserted-by":"publisher","first-page":"8809","DOI":"10.3390\/ijms21228809","volume":"21","author":"MF Adasme","year":"2020","unstructured":"Adasme MF, Bolz SN, Adelmann L, Salentin S, Haupt VJ, Moreno-Rodr\u00edguez A, Nogueda-Torres B, Castillo-Campos V, Yepez-Mulia L, Fuentes-Vicente JAD et al (2020) Repositioned drugs for Chagas disease unveiled via structure-based drug repositioning. Int J Mol Sci 21(22):8809","journal-title":"Int J Mol Sci"},{"key":"592_CR12","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1016\/j.csbj.2021.06.013","volume":"19","author":"SN Bolz","year":"2021","unstructured":"Bolz SN, Salentin S, Jennings G, Haupt VJ, Sterneckert J, Schroeder M (2021) Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor. Comput Struct Biotechnol J 19:3674\u20133681","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"592_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nrd2199","volume":"5","author":"JP Overington","year":"2006","unstructured":"Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5(12):993\u2013996","journal-title":"Nat Rev Drug Discov"},{"issue":"D1","key":"592_CR14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/nar\/gks966","volume":"41","author":"J Yang","year":"2012","unstructured":"Yang J, Roy A, Zhang Y (2012) BioLiP: a semi-manually curated database for biologically relevant ligand\u2013protein interactions. Nucleic Acids Res 41(D1):1096\u20131103","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"592_CR15","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1073\/pnas.1321614111","volume":"111","author":"K Khafizov","year":"2014","unstructured":"Khafizov K, Madrid-Aliste C, Almo SC, Fiser A (2014) Trends in structural coverage of the protein universe and the impact of the protein structure initiative. Proc Nat Acad Sci 111(10):3733\u20133738","journal-title":"Proc Nat Acad Sci"},{"issue":"7","key":"592_CR16","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1073\/pnas.78.7.4046","volume":"78","author":"WP Jencks","year":"1981","unstructured":"Jencks WP (1981) On the attribution and additivity of binding energies. Proc Nat Acad Sci 78(7):4046\u20134050","journal-title":"Proc Nat Acad Sci"},{"issue":"10","key":"592_CR17","doi-asserted-by":"publisher","first-page":"1700042","DOI":"10.1002\/minf.201700042","volume":"36","author":"MN Drwal","year":"2017","unstructured":"Drwal MN, Bret G, Kellenberger E (2017) Multi-target fragments display versatile binding modes. Mol Informat 36(10):1700042","journal-title":"Mol Informat"},{"issue":"20","key":"592_CR18","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1073\/pnas.1501567112","volume":"112","author":"D Kozakov","year":"2015","unstructured":"Kozakov D, Hall DR, Jehle S, Luo L, Ochiana SO, Jones EV, Pollastri M, Allen KN, Whitty A, Vajda S (2015) Ligand deconstruction: why some fragment binding positions are conserved and others are not. Proc Nat Acad Sci 112(20):2585\u20132594","journal-title":"Proc Nat Acad Sci"},{"issue":"14","key":"592_CR19","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1021\/acs.jmedchem.8b00256","volume":"61","author":"MN Drwal","year":"2018","unstructured":"Drwal MN, Bret G, Perez C, Jacquemard C, Desaphy J, Kellenberger E (2018) Structural insights on fragment binding mode conservation. J Med Chem 61(14):5963\u20135973","journal-title":"J Med Chem"},{"issue":"7","key":"592_CR20","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1021\/acs.jmedchem.8b01855","volume":"62","author":"F Giordanetto","year":"2019","unstructured":"Giordanetto F, Jin C, Willmore L, Feher M, Shaw DE (2019) Fragment hits: what do they look like and how do they bind? J Med Chem 62(7):3381\u20133394","journal-title":"J Med Chem"},{"issue":"3","key":"592_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1021\/ci970429i","volume":"38","author":"XQ Lewell","year":"1998","unstructured":"Lewell XQ, Judd DB, Watson SP, Hann MM (1998) Recap retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inform Comput Sci 38(3):511\u2013522","journal-title":"J Chem Inform Comput Sci"},{"issue":"1","key":"592_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cbdv.200490173","volume":"2","author":"IM Lagoja","year":"2005","unstructured":"Lagoja IM (2005) Pyrimidine as constituent of natural biologically active compounds. Chem Biodiver 2(1):1\u201350","journal-title":"Chem Biodiver"},{"issue":"D1","key":"592_CR23","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/nar\/gky1075","volume":"47","author":"D Mendez","year":"2019","unstructured":"Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, F\u00e9lix E, Magari\u00f1os MP, Mosquera JF, Mutowo P, Nowotka M et al (2019) ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res 47(D1):930\u2013940","journal-title":"Nucleic Acids Res"},{"key":"592_CR24","doi-asserted-by":"crossref","unstructured":"Li J, Lu Z (2012) A new method for computational drug repositioning using drug pairwise similarity, 1\u20134 . IEEE","DOI":"10.1109\/BIBM.2012.6392722"},{"issue":"6","key":"592_CR25","doi-asserted-by":"publisher","first-page":"65894","DOI":"10.1371\/journal.pone.0065894","volume":"8","author":"VJ Haupt","year":"2013","unstructured":"Haupt VJ, Daminelli S, Schroeder M (2013) Drug promiscuity in pdb: protein binding site similarity is key. PLoS One 8(6):65894","journal-title":"PLoS One"},{"key":"592_CR26","doi-asserted-by":"crossref","unstructured":"Kumar S, Kumar S (2019) Molecular docking: a structure-based approach for drug repurposing. 161\u2013189","DOI":"10.1016\/B978-0-12-816125-8.00006-7"},{"issue":"1","key":"592_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-2946-3-1","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open Babel: an open chemical toolbox. J Cheminformat 3(1):1\u201314","journal-title":"J Cheminformat"},{"key":"592_CR28","doi-asserted-by":"crossref","unstructured":"Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ, Schroeder M (2021) PLIP 2021: expanding the scope of the protein\u2013ligand interaction profiler to DNA and RNA. Nucleic Acids Res","DOI":"10.1093\/nar\/gkab294"},{"issue":"3","key":"592_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter JD (2007) Matplotlib: a 2D graphics environment. Comput Sci Eng 9(3):90\u201395","journal-title":"Comput Sci Eng"}],"container-title":["Journal of Cheminformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-022-00592-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13321-022-00592-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-022-00592-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T12:12:57Z","timestamp":1647346377000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcheminf.biomedcentral.com\/articles\/10.1186\/s13321-022-00592-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1186\/s13321-022-00592-w","relation":{},"ISSN":["1758-2946"],"issn-type":[{"value":"1758-2946","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"14 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}